Leila Abdelmoula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leila Abdelmoula has a total of 650 co-authors. Here are the top co-authors by number of shared publications:
- Raoudha Tekaya
Department of Rheumatology, Charles Nicolle Hospital, Tunis, Tunisia
34 shared publications Rafik Zouari
Service de Rhumatologie, Hôpital Charles Nicolle, Tunis Tunisie
27 shared publicationsLilia Chaabouni
Hôpital Charles-Nicolle, service de rhumatologie, Tunis, Tunisie
25 shared publications- Olfa Saidane
Department of Rheumatology, Charles Nicolle Hospital, Tunis, Tunisia
22 shared publications R. Zouari
Rheumatology, hopital charles nicole, Tunis, Tunisia
20 shared publicationsChiraz Ben Hadj Yahia
16 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 62
Clinical, biochemical, and radiological features of osteomalacia: evaluation of diagnostic approaches in a retrospective study of 33 cases
Introduction: Osteomalacia is a generalized bone disorder characterized by defective bone mineralization. Definitive etiological diagnoses of osteomalacia remain challenging and are not fully standardized. We aim to describe clinical, biochemical, and radiographic features, elucidate the utility of various diagnosis methods, and propose a diagnostic strategy. Methods: A retrospective study involving 33 patients with osteomalacia over a 15-year period at our Rheumatology Department. Results: The mean age was 50.6 years (range: 17-87 years), with a female predominance (sex-ratio=0.18). Clinical signs included bone pain (87.8%), gait disturbance (63.6%), motor deficit (54.5%), clinically apparent bone deformity (21.2%), fragility fracture (24.2%), and muscle pain (42.2%). Radiologically, diffuse bone demineralization was observed in 91% of patients. Other signs included Looser Milkman streaks (60.6%), bone deformities (39.5%), and bone fractures (55%). Low bone mineral density was observed in 85% of tested patients while 60% of them had densitometric osteoporosis. Main biochemical disorders included increased alkaline phosphatase levels (85%), hypocalcemia (88%), and hypophosphatemia (61%). Parathyroid hormone levels were elevated in 82% of cases, 25-hydroxyvitamin D level was reduced in all cases. All patients in our study fulfilled both the McKenna and the Adrar indexes for osteomalacia diagnosis. Both diagnostic indexes were significantly and positively correlated (r=0.56, p=0.01). Vitamin D-related osteomalacia was the predominant etiology, with vitamin D malabsorption observed in nine patients, seven of whom had celiac disease. Chronic kidney failure was observed in five cases. Osteomalacia was associated with renal phosphate leak in four cases. Conclusion: The presentation and etiologies of osteomalacia are diverse. Diagnosis relies on clinical, biochemical, and radiological findings and can be aided by diagnostic indexes such as McKenna's and Adrar's. Bone biopsy should be reserved for cases where the diagnosis is doubtful.
- 20 July 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 62
Open AccessClinical, biochemical, and radiological features of osteomalacia: evaluation of diagnostic approaches in a retrospective study of 33 cases
Introduction: Osteomalacia is a generalized bone disorder characterized by defective bone mineralization. Definitive etiological diagnoses of osteomalacia remain challenging and are not fully standardized. We aim to describe clinical, biochemical, and radiographic features, elucidate the utility of various diagnosis methods, and propose a diagnostic strategy. Methods: A retrospective study involving 33 patients with osteomalacia over a 15-year period at our Rheumatology Department. Results: The mean age was 50.6 years (range: 17-87 years), with a female predominance (sex-ratio=0.18). Clinical signs included bone pain (87.8%), gait disturbance (63.6%), motor deficit (54.5%), clinically apparent bone deformity (21.2%), fragility fracture (24.2%), and muscle pain (42.2%). Radiologically, diffuse bone demineralization was observed in 91% of patients. Other signs included Looser Milkman streaks (60.6%), bone deformities (39.5%), and bone fractures (55%). Low bone mineral density was observed in 85% of tested patients while 60% of them had densitometric osteoporosis. Main biochemical disorders included increased alkaline phosphatase levels (85%), hypocalcemia (88%), and hypophosphatemia (61%). Parathyroid hormone levels were elevated in 82% of cases, 25-hydroxyvitamin D level was reduced in all cases. All patients in our study fulfilled both the McKenna and the Adrar indexes for osteomalacia diagnosis. Both diagnostic indexes were significantly and positively correlated (r=0.56, p=0.01). Vitamin D-related osteomalacia was the predominant etiology, with vitamin D malabsorption observed in nine patients, seven of whom had celiac disease. Chronic kidney failure was observed in five cases. Osteomalacia was associated with renal phosphate leak in four cases. Conclusion: The presentation and etiologies of osteomalacia are diverse. Diagnosis relies on clinical, biochemical, and radiological findings and can be aided by diagnostic indexes such as McKenna's and Adrar's. Bone biopsy should be reserved for cases where the diagnosis is doubtful.
- 16 April 2026
- Published by Taylor & Francis in Archives of Environmental & Occupational Health
- Vol. 81 (5-6) , 105-112
Impact of an ergonomic training program on musculoskeletal disorders among paramedical staff: A comparative study
Musculoskeletal disorders (MSDs) are a major occupational health concern among paramedical staff, leading to pain, reduced performance, and absenteeism. This prospective interventional comparative study included all 80 paramedical staff members at the center who met the inclusion criteria, making the study population exhaustive. Participants were assigned to an intervention group (n = 40) receiving a three-session ergonomic training program or a control group (n = 40) receiving usual practice. Primary outcomes were MSD prevalence and absenteeism; the secondary outcome was quality of life (SF-36). Assessments were conducted at baseline (T0) and 6 months (T6). After 6 months, the intervention group reported a significant reduction in MSD prevalence in the cervical spine (from 55% to 30%, p = 0.01), shoulders (55% to 35%, p = 0.03), hands (40% to 20%, p = 0.008), and fingers (35% to 20%, p = 0.03) compared to baseline and to the control group. Absenteeism days decreased significantly in the intervention group (from 14 ± 7 to 8 ± 4 days, p = 0.03). No significant change was observed in overall SF-36 scores. The ergonomic training program was associated with reductions in MSD prevalence and absenteeism among paramedical staff.
- 16 April 2026
- Published by Taylor & Francis in Archives of Environmental & Occupational Health
- Vol. 81 (5-6) , 105-112
Impact of an ergonomic training program on musculoskeletal disorders among paramedical staff: A comparative study
Musculoskeletal disorders (MSDs) are a major occupational health concern among paramedical staff, leading to pain, reduced performance, and absenteeism. This prospective interventional comparative study included all 80 paramedical staff members at the center who met the inclusion criteria, making the study population exhaustive. Participants were assigned to an intervention group (n = 40) receiving a three-session ergonomic training program or a control group (n = 40) receiving usual practice. Primary outcomes were MSD prevalence and absenteeism; the secondary outcome was quality of life (SF-36). Assessments were conducted at baseline (T0) and 6 months (T6). After 6 months, the intervention group reported a significant reduction in MSD prevalence in the cervical spine (from 55% to 30%, p = 0.01), shoulders (55% to 35%, p = 0.03), hands (40% to 20%, p = 0.008), and fingers (35% to 20%, p = 0.03) compared to baseline and to the control group. Absenteeism days decreased significantly in the intervention group (from 14 ± 7 to 8 ± 4 days, p = 0.03). No significant change was observed in overall SF-36 scores. The ergonomic training program was associated with reductions in MSD prevalence and absenteeism among paramedical staff.
- Open Access
- 26 March 2026
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 64 (2) , 132-138
Neuropathic pain in rheumatoid arthritis: prevalence and associated factors
Introduction: This study aimed to assess the prevalence of neuropathic pain in rheumatoid arthritis (RA) patients, and to identify associated factors. Material and methods: We conducted a cross-sectional study in patients with RA. Neuropathic pain was evaluated using the DN4 (Douleur Neuropathique 4) and PainDETECT scores. Agreement between the 2 questionnaires was estimated through Cohen’s k. Factors associated with neuropathic pain were assessed. Results: A total of 121 patients with RA were included, with a mean age of 57 ±12.2 years, and a predominance of women (83%). The mean duration of RA was 16 ±1.0 years. The mean Disease Activity Score in 28 joints (DAS28) was 4.28 ±1.0, indicating moderate activity of the RA. According to the DN4 score, 61.2% of patients had neuropathic pain, and according to the PainDETECT score, 47.1% of patients were identified as having possible or likely neuropathic pain. Eighty-four patients (69.4%) had a positive DN4 score and/or a positive PainDETECT score. The coefficient of agreement k between the 2 tests was 0.233, indicating a fair agreement. Factors significantly associated with the presence of neuropathic pain were: female sex (p = 0.01), prolonged morning stiffness duration (p = 0.01), number of painful joints (p = 0.01), and number of swollen joints (p = 0.03). Additionally, the use of glucocorticosteroids (p = 0.001), analgesics (p = 0.03) and anti-CD20 drugs (p = 0.03) were significantly associated with neuropathic. Conclusions: Our study suggests a potentially high prevalence of neuropathic pain in patients with RA, highlighting the need for early detection and appropriate management.
- 26 March 2026
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 64 (2) , 132-138
Open AccessNeuropathic pain in rheumatoid arthritis: prevalence and associated factors
Introduction: This study aimed to assess the prevalence of neuropathic pain in rheumatoid arthritis (RA) patients, and to identify associated factors. Material and methods: We conducted a cross-sectional study in patients with RA. Neuropathic pain was evaluated using the DN4 (Douleur Neuropathique 4) and PainDETECT scores. Agreement between the 2 questionnaires was estimated through Cohen’s k. Factors associated with neuropathic pain were assessed. Results: A total of 121 patients with RA were included, with a mean age of 57 ±12.2 years, and a predominance of women (83%). The mean duration of RA was 16 ±1.0 years. The mean Disease Activity Score in 28 joints (DAS28) was 4.28 ±1.0, indicating moderate activity of the RA. According to the DN4 score, 61.2% of patients had neuropathic pain, and according to the PainDETECT score, 47.1% of patients were identified as having possible or likely neuropathic pain. Eighty-four patients (69.4%) had a positive DN4 score and/or a positive PainDETECT score. The coefficient of agreement k between the 2 tests was 0.233, indicating a fair agreement. Factors significantly associated with the presence of neuropathic pain were: female sex (p = 0.01), prolonged morning stiffness duration (p = 0.01), number of painful joints (p = 0.01), and number of swollen joints (p = 0.03). Additionally, the use of glucocorticosteroids (p = 0.001), analgesics (p = 0.03) and anti-CD20 drugs (p = 0.03) were significantly associated with neuropathic. Conclusions: Our study suggests a potentially high prevalence of neuropathic pain in patients with RA, highlighting the need for early detection and appropriate management.
- Open Access
- 11 November 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (5) , 337-347
Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review
Introduction: Biological treatments are indicated in familial Mediterranean fever (FMF) patients with colchicine resistance or intolerance. Interleukin-1 (IL-1) inhibitors may not yield sufficient efficacy and safety. Interleukin-6 inhibitors (tocilizumab – TCZ) have been suggested to be potentially beneficial. This systematic literature review aimed to evaluate the existing data on the efficacy and safety of IL-6 inhibitors in the treatment of FMF. Material and Methods: A systematic literature review was conducted using PubMed, Embase, Scopus, Web of Science, and the Cochrane Library to identify literature published until February 2024 on “Tocilizumab” OR “Interleukin-6 inhibitor” AND “Familial Mediterranean Fever”. This study was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Results: A total of 11 studies were included, corresponding to 68 patients: 6 studies were case reports, 3 were case series, and 2 were randomized control trials. Tocilizumab was indicated mainly for amyloid A (AA) amyloidosis and resistance/intolerance to other drugs. Tocilizumab showed efficacy in controlling FMF attacks and disease symptoms including fever, abdominal pain, arthritis and arthralgia. Inflammatory markers including C-reactive protein and serum amyloid A protein decreased. A decrease in proteinuria levels was reported in 20 patients. Adverse events were recorded in one-third of patients and led to TCZ discontinuation in 5 patients. No deaths associated with anti-IL-6 treatment were documented within a median follow-up period of 13 months. Conclusions: Although the duration of follow-up of TCZ was short, we concluded that TCZ might present an acceptable profile regarding efficacy and safety in adult FMF patients. Our data suggest that TCZ could be a good treatment option after IL-1 inhibitors and warrants further investigation.
- 11 November 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (5) , 337-347
Open AccessEfficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review
Introduction: Biological treatments are indicated in familial Mediterranean fever (FMF) patients with colchicine resistance or intolerance. Interleukin-1 (IL-1) inhibitors may not yield sufficient efficacy and safety. Interleukin-6 inhibitors (tocilizumab – TCZ) have been suggested to be potentially beneficial. This systematic literature review aimed to evaluate the existing data on the efficacy and safety of IL-6 inhibitors in the treatment of FMF. Material and Methods: A systematic literature review was conducted using PubMed, Embase, Scopus, Web of Science, and the Cochrane Library to identify literature published until February 2024 on “Tocilizumab” OR “Interleukin-6 inhibitor” AND “Familial Mediterranean Fever”. This study was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Results: A total of 11 studies were included, corresponding to 68 patients: 6 studies were case reports, 3 were case series, and 2 were randomized control trials. Tocilizumab was indicated mainly for amyloid A (AA) amyloidosis and resistance/intolerance to other drugs. Tocilizumab showed efficacy in controlling FMF attacks and disease symptoms including fever, abdominal pain, arthritis and arthralgia. Inflammatory markers including C-reactive protein and serum amyloid A protein decreased. A decrease in proteinuria levels was reported in 20 patients. Adverse events were recorded in one-third of patients and led to TCZ discontinuation in 5 patients. No deaths associated with anti-IL-6 treatment were documented within a median follow-up period of 13 months. Conclusions: Although the duration of follow-up of TCZ was short, we concluded that TCZ might present an acceptable profile regarding efficacy and safety in adult FMF patients. Our data suggest that TCZ could be a good treatment option after IL-1 inhibitors and warrants further investigation.
- Open Access
- 18 March 2024
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 62 (1) , 35-42
Burden of disease, pain catastrophizing, and central sensitization in relation to work-related issues in young spondyloarthritis patients
Introduction: Spondyloarthritis (SpA) is a common rheumatic inflammatory disease and can impact patients’ work productivity. We aimed to evaluate the impact of pain catastrophizing and central sensitization on work outcomes in young SpA patients and determine the predictive factors of work productivity loss.Material and methods: We performed a cross-sectional study over 6 months. We included patients aged between 18 and 50 years old, diagnosed with axial or peripheral SpA. Pain catastrophizing and central sensitization were assessed using the Pain Catastrophizing Scale (PCS) and Central Sensitization Inventory (CSI) questionnaire, respectively. Impact of SpA on work productivity and activity impairment during and out-side of work was measured with the Work Productivity and Activity Impairment Questionnaire (WPAI: Spondyloarthritis).Results: A total of 72 patients were enrolled, with a median age of 39 years (28.3–46), 65.3% men, and 54.4% working patients. Median scores of activity impairment outside of work, and work productivity loss were 50% (40–70), and 50% (40–60), respectively. Median absenteeism and presenteeism scores were 0% (IQR 0–7), and 100% (IQR 86.5–100), respectively. Regarding work-related outcomes: activity impairment was positively correlated with CSI and PCS; presenteeism was significantly associated with male sex (p = 0.009); and work productivity loss was positively associated with anxiety, depression, and poor quality of life. Multivariate regression analysis identified predictive factors of work productivity loss: male sex, poor quality of life, and prolonged morning stiffness.Conclusions: Assessment of the impact of pain catastrophizing and central sensitization on work-related outcomes in patients with SpA is important to understand the burden of illness and to identify early those in need of interventions in clinical practice.
- 18 March 2024
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 62 (1) , 35-42
Open AccessBurden of disease, pain catastrophizing, and central sensitization in relation to work-related issues in young spondyloarthritis patients
Introduction: Spondyloarthritis (SpA) is a common rheumatic inflammatory disease and can impact patients’ work productivity. We aimed to evaluate the impact of pain catastrophizing and central sensitization on work outcomes in young SpA patients and determine the predictive factors of work productivity loss.Material and methods: We performed a cross-sectional study over 6 months. We included patients aged between 18 and 50 years old, diagnosed with axial or peripheral SpA. Pain catastrophizing and central sensitization were assessed using the Pain Catastrophizing Scale (PCS) and Central Sensitization Inventory (CSI) questionnaire, respectively. Impact of SpA on work productivity and activity impairment during and out-side of work was measured with the Work Productivity and Activity Impairment Questionnaire (WPAI: Spondyloarthritis).Results: A total of 72 patients were enrolled, with a median age of 39 years (28.3–46), 65.3% men, and 54.4% working patients. Median scores of activity impairment outside of work, and work productivity loss were 50% (40–70), and 50% (40–60), respectively. Median absenteeism and presenteeism scores were 0% (IQR 0–7), and 100% (IQR 86.5–100), respectively. Regarding work-related outcomes: activity impairment was positively correlated with CSI and PCS; presenteeism was significantly associated with male sex (p = 0.009); and work productivity loss was positively associated with anxiety, depression, and poor quality of life. Multivariate regression analysis identified predictive factors of work productivity loss: male sex, poor quality of life, and prolonged morning stiffness.Conclusions: Assessment of the impact of pain catastrophizing and central sensitization on work-related outcomes in patients with SpA is important to understand the burden of illness and to identify early those in need of interventions in clinical practice.
- 17 June 2023
- Published by Wiley in Musculoskeletal Care
- Vol. 21 (4) , 1098-1104
Psoriatic Arthritis Quality of Life questionnaire: Translation, cultural adaptation and validation into Arabic language
Background: Psoriatic arthritis (PsA) is a multifaceted inflammatory disease that has a strong negative impact on the quality of life (QoL) of patients. The Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire was the first disease‐specific patient‐derived instrument developed to measure the QoL in patients with PsA. Our objective was to translate the PsAQol into Arabic language and evaluate its reliability and validity in patients with PsA.Methods: This was a cross‐sectional study including patients with PsA. A clinical and biological assessment of the patients was performed at inclusion. The translation of the original PsAQoL into Arabic was performed by a professional bilingual and lay panel. Eight patients were interviewed to assess face and content validity. A separate sample of PsA patients (n = 30) were invited to participate in a test‐retest postal study in order to investigate reproducibility and construct validity. One week separated the two administrations. The Arabic version of Health Assessment Questionnaire (HAQ) was used as a comparator instrument for convergent validity.Results: Face and content validity were satisfactory. The Arabic version of the PsAQoL was found to be relevant, understandable and easy to complete in only a few minutes. One item was excluded (item 16). It had no correlation with either the other 19 items or the total score of PsAQol. The Arabic PsAQol had excellent internal consistency (Cronbach's a = 0.926), and test‐retest reliability (r = 0.982). There was a positive correlation between the total score of the PsAQoL and the Arabic version of HAQ (Spearman's r = 0.838, p < 10−3). Exploratory factor analysis had extracted two factors explaining 55% of the total variance.Conclusion: Nineteen items were selected to compose the Arabic version of PsAQoL, which was found to be relevant and understandable and has excellent reliability and construct validity. The new measure will be a valuable new tool for use in routine care for patients' assessment.
- 17 June 2023
- Published by Wiley in Musculoskeletal Care
- Vol. 21 (4) , 1098-1104
Psoriatic Arthritis Quality of Life questionnaire: Translation, cultural adaptation and validation into Arabic language
Background: Psoriatic arthritis (PsA) is a multifaceted inflammatory disease that has a strong negative impact on the quality of life (QoL) of patients. The Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire was the first disease‐specific patient‐derived instrument developed to measure the QoL in patients with PsA. Our objective was to translate the PsAQol into Arabic language and evaluate its reliability and validity in patients with PsA.Methods: This was a cross‐sectional study including patients with PsA. A clinical and biological assessment of the patients was performed at inclusion. The translation of the original PsAQoL into Arabic was performed by a professional bilingual and lay panel. Eight patients were interviewed to assess face and content validity. A separate sample of PsA patients (n = 30) were invited to participate in a test‐retest postal study in order to investigate reproducibility and construct validity. One week separated the two administrations. The Arabic version of Health Assessment Questionnaire (HAQ) was used as a comparator instrument for convergent validity.Results: Face and content validity were satisfactory. The Arabic version of the PsAQoL was found to be relevant, understandable and easy to complete in only a few minutes. One item was excluded (item 16). It had no correlation with either the other 19 items or the total score of PsAQol. The Arabic PsAQol had excellent internal consistency (Cronbach's a = 0.926), and test‐retest reliability (r = 0.982). There was a positive correlation between the total score of the PsAQoL and the Arabic version of HAQ (Spearman's r = 0.838, p < 10−3). Exploratory factor analysis had extracted two factors explaining 55% of the total variance.Conclusion: Nineteen items were selected to compose the Arabic version of PsAQoL, which was found to be relevant and understandable and has excellent reliability and construct validity. The new measure will be a valuable new tool for use in routine care for patients' assessment.
- Open Access
- 21 December 2022
- Published by Springer Nature in BMC Rheumatology
- Vol. 6 (1) , 1-8
Association between Rheumatic Disease Comorbidity Index and factors of poor prognosis in a cohort of 280 patients with rheumatoid arthritis
Background: Rheumatoid arthritis (RA) is commonly associated with higher rates of comorbidities. Recent recommendations highlight screening comorbidities during the disease course because of their impact on patients’ ability to function, on disease outcome, but also on treatment choices. Hence the interest of our study that aimed to quantify the impact of comorbidities among RA patients using a validated tool the Rheumatic Disease Comorbidity Index (RDCI) and to explore the association between comorbidities and disease characteristics. Methods: We conducted a cross-sectional study over 12 months period, including patients followed for an established RA according to the ACR/EULAR 2010 criteria and hospitalized in our rheumatology department. Patients’ characteristics and disease features were collected for each patient. Comorbidities were quantified using the RDCI. We looked for the association between RDCI and patients characteristics and RA parameters. Univariable and multivariable analysis were made. Results: They were 280 patients: 233 female (83.2%) and 47 male (16.8%) with a mean age of 58.07 (SD 11.12) years. The mean follow-up period was 14.74 (SD 1.63) years. Comorbidities were noted in 133 patients (47.5%). The mean comorbidity score measured by the RDCI was 1.05 (SD 1.23). RDCI was positively correlated with age (p < 0.001, r = 0.359). RA patients whose age of disease onset exceeds 40 years have significantly higher RDCI (1.8 (SD 1.3) [CI 95%: 1.36–1.88] vs. 1.5 (SD 1.2), p = 0.007). Moreover, RDCI was significantly associated with the presence pulmonary involvement (p < 0.001) and ocular involvement (p = 0.002). RDCI was also associated with erosive RA (p = 0.006), the presence of atlanto-axial dislocation (p = 0.014), and coxitis (p = 0.029). Regarding therapy regimen, RDCI was statistically increased in patients receiving bDMARDs compared to patients under csDMARDs (2.8 (SD 1.6) vs. 1.0 (SD 1.0), p = 0.021). Conclusion: In this study, comorbidity index was associated with signs of poor prognosis such as erosions, coxitis, and atlanto-axial dislocation. This confirmed the hypothesis that comorbidity can be a threat to the improvement in the long-term prognosis in RA patients.
- 21 December 2022
- Published by Springer Nature in BMC Rheumatology
- Vol. 6 (1) , 1-8
Open AccessAssociation between Rheumatic Disease Comorbidity Index and factors of poor prognosis in a cohort of 280 patients with rheumatoid arthritis
Background: Rheumatoid arthritis (RA) is commonly associated with higher rates of comorbidities. Recent recommendations highlight screening comorbidities during the disease course because of their impact on patients’ ability to function, on disease outcome, but also on treatment choices. Hence the interest of our study that aimed to quantify the impact of comorbidities among RA patients using a validated tool the Rheumatic Disease Comorbidity Index (RDCI) and to explore the association between comorbidities and disease characteristics. Methods: We conducted a cross-sectional study over 12 months period, including patients followed for an established RA according to the ACR/EULAR 2010 criteria and hospitalized in our rheumatology department. Patients’ characteristics and disease features were collected for each patient. Comorbidities were quantified using the RDCI. We looked for the association between RDCI and patients characteristics and RA parameters. Univariable and multivariable analysis were made. Results: They were 280 patients: 233 female (83.2%) and 47 male (16.8%) with a mean age of 58.07 (SD 11.12) years. The mean follow-up period was 14.74 (SD 1.63) years. Comorbidities were noted in 133 patients (47.5%). The mean comorbidity score measured by the RDCI was 1.05 (SD 1.23). RDCI was positively correlated with age (p < 0.001, r = 0.359). RA patients whose age of disease onset exceeds 40 years have significantly higher RDCI (1.8 (SD 1.3) [CI 95%: 1.36–1.88] vs. 1.5 (SD 1.2), p = 0.007). Moreover, RDCI was significantly associated with the presence pulmonary involvement (p < 0.001) and ocular involvement (p = 0.002). RDCI was also associated with erosive RA (p = 0.006), the presence of atlanto-axial dislocation (p = 0.014), and coxitis (p = 0.029). Regarding therapy regimen, RDCI was statistically increased in patients receiving bDMARDs compared to patients under csDMARDs (2.8 (SD 1.6) vs. 1.0 (SD 1.0), p = 0.021). Conclusion: In this study, comorbidity index was associated with signs of poor prognosis such as erosions, coxitis, and atlanto-axial dislocation. This confirmed the hypothesis that comorbidity can be a threat to the improvement in the long-term prognosis in RA patients.
- 3 December 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (4) , 979-997
Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis
Sarcopenia is a syndrome defined by generalized and progressive loss of skeletal muscle mass, strength, and function. Besides affecting elderly population, it is actually common among inflammatory rheumatic diseases (IRD) patients. We performed a systematic literature review with a meta-analysis to investigate the influence of biologic and target synthetic disease-modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) on sarcopenia in IRD. A systematic search has been performed on Pubmed, Scopus, and Web of science. Studies characteristics were collected. Assessment tools were body composition (total lean mass (TLM) and percentage, appendicular skeletal mass (ASM), fat-free mass and index (FFM and FFMI), skeletal mass index (SMI) and segmental lean mass (SLM)), and muscle strength and physical performance tests. Treatment effect defined the difference in change from baseline to the end of follow-up treatment was divided by the pooled SD of the difference. Twenty-two studies on 778 patients receiving bDMARDs/tsDMARDs and 157 controls were reviewed. They investigated rheumatoid arthritis (RA) (N = 14), spondyloarthritis (SpA) (N = 6), psoriatic arthritis (N = 1), and both RA and SpA (N = 1). tsDMARDs were used in one study with no effect on sarcopenia. Ten studies demonstrated that bDMARDs increased significantly muscle measures in 347 patients (44.6%) with a significant increase in TLM (6/15 studies; 57.4%), FFMI (4/6 studies; 59.9%), ASM (2/5 studies; 17.6%), SMI (2/5 studies; 18.1%), and SLM (2/2 studies; 3.6%). bDMARDs showed also a positive effect on handgrip strength in 1/3 of studies (45.2%) and on physical performance in 1/2 of studies (61%). In 1/5 of comparative studies, IRD patients on bDMARDs showed significantly higher increase of TLM in comparison to controls naïve bDMARDs. Regarding diagnosis, positive effect of bDMARDs was seen in 67.4% in SpA versus 49.3% in RA, with a significant increase of TLM, ASM and FFMI in 59.4%, 100%, and 65.2% in SpA versus 54.9%, 24.1%, and 54.8% in RA, respectively. Meta-analysis assessed the effect of bDMARD on TLM in 10 studies. There was no statistically significant difference [SMD − 0.10 (95% Confidence Interval − 0.26 − 0.06; tau2 = 0). Heterogeneity across studies was null, and the 95% confidence interval (index of precision) was equal to the 95% predictive interval. The first systematic literature review showed that bDMARDs have a significant improve effect in nearly half of RA and SpA patients on muscle mass and muscle strength, assessed separately. However, the meta-analysis concluded that bDMARDs have no significant effect on TLM.
- 3 December 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (4) , 979-997
Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis
Sarcopenia is a syndrome defined by generalized and progressive loss of skeletal muscle mass, strength, and function. Besides affecting elderly population, it is actually common among inflammatory rheumatic diseases (IRD) patients. We performed a systematic literature review with a meta-analysis to investigate the influence of biologic and target synthetic disease-modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) on sarcopenia in IRD. A systematic search has been performed on Pubmed, Scopus, and Web of science. Studies characteristics were collected. Assessment tools were body composition (total lean mass (TLM) and percentage, appendicular skeletal mass (ASM), fat-free mass and index (FFM and FFMI), skeletal mass index (SMI) and segmental lean mass (SLM)), and muscle strength and physical performance tests. Treatment effect defined the difference in change from baseline to the end of follow-up treatment was divided by the pooled SD of the difference. Twenty-two studies on 778 patients receiving bDMARDs/tsDMARDs and 157 controls were reviewed. They investigated rheumatoid arthritis (RA) (N = 14), spondyloarthritis (SpA) (N = 6), psoriatic arthritis (N = 1), and both RA and SpA (N = 1). tsDMARDs were used in one study with no effect on sarcopenia. Ten studies demonstrated that bDMARDs increased significantly muscle measures in 347 patients (44.6%) with a significant increase in TLM (6/15 studies; 57.4%), FFMI (4/6 studies; 59.9%), ASM (2/5 studies; 17.6%), SMI (2/5 studies; 18.1%), and SLM (2/2 studies; 3.6%). bDMARDs showed also a positive effect on handgrip strength in 1/3 of studies (45.2%) and on physical performance in 1/2 of studies (61%). In 1/5 of comparative studies, IRD patients on bDMARDs showed significantly higher increase of TLM in comparison to controls naïve bDMARDs. Regarding diagnosis, positive effect of bDMARDs was seen in 67.4% in SpA versus 49.3% in RA, with a significant increase of TLM, ASM and FFMI in 59.4%, 100%, and 65.2% in SpA versus 54.9%, 24.1%, and 54.8% in RA, respectively. Meta-analysis assessed the effect of bDMARD on TLM in 10 studies. There was no statistically significant difference [SMD − 0.10 (95% Confidence Interval − 0.26 − 0.06; tau2 = 0). Heterogeneity across studies was null, and the 95% confidence interval (index of precision) was equal to the 95% predictive interval. The first systematic literature review showed that bDMARDs have a significant improve effect in nearly half of RA and SpA patients on muscle mass and muscle strength, assessed separately. However, the meta-analysis concluded that bDMARDs have no significant effect on TLM.
- 27 September 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (1) , 285-291
Tophaceous gout in a young man with Gitelman syndrome: a case report with an overview
Gitelman syndrome represents the clinical manifestations of inactivation of the Slc12a3 genes encoding the thiazide-sensitive sodium chloride cotransporter and the Trpm6-Mg genes encoding the magnesium transporters in the distal convoluted tubule. In fact, the biochemical findings resemble those with thiazide diuretics such as hypokalemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis, and low normal blood pressure. He is usually associated with calcium pyrophosphate deposition. Serum uricemia level is rarely affected in Gitelman syndrome. We aimed to report a rare association of chronic gout with Gitelman syndrome, hence the interest of our case. We describe a 29-year-old male patient with a history of Gitelman syndrome associated with articular gout including pelvic localization. We provided pictorial evidence of extensive and diffuse monosodium urate deposition in articular and periarticular structures to confirm the gout origin. A literature review illustrates 4 reported cases of Gitelman syndrome associated with gout. The gender distribution was equal with a mean age of 40 years. Key Points • Gouty arthritis and Gitelman syndrome is a rare association. • Gitelman syndrome may be a new risk factor for the development of gout, due to its thiazide-like effect.
- 27 September 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (1) , 285-291
Tophaceous gout in a young man with Gitelman syndrome: a case report with an overview
Gitelman syndrome represents the clinical manifestations of inactivation of the Slc12a3 genes encoding the thiazide-sensitive sodium chloride cotransporter and the Trpm6-Mg genes encoding the magnesium transporters in the distal convoluted tubule. In fact, the biochemical findings resemble those with thiazide diuretics such as hypokalemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis, and low normal blood pressure. He is usually associated with calcium pyrophosphate deposition. Serum uricemia level is rarely affected in Gitelman syndrome. We aimed to report a rare association of chronic gout with Gitelman syndrome, hence the interest of our case. We describe a 29-year-old male patient with a history of Gitelman syndrome associated with articular gout including pelvic localization. We provided pictorial evidence of extensive and diffuse monosodium urate deposition in articular and periarticular structures to confirm the gout origin. A literature review illustrates 4 reported cases of Gitelman syndrome associated with gout. The gender distribution was equal with a mean age of 40 years. Key Points • Gouty arthritis and Gitelman syndrome is a rare association. • Gitelman syndrome may be a new risk factor for the development of gout, due to its thiazide-like effect.
- 1 July 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (10) , 3017-3025
Increased epicardial adipose tissue thickness correlates with endothelial dysfunction in spondyloarthritis
Introduction We aimed to investigate the relationship between epicardial adipose tissue (EAT) thickness, flow-mediated dilation (FMD), and carotid intima-media thickness (cIMT) in spondyloarthritis (SpA) patients compared to healthy controls. Methods We performed a cross-sectional study including SpA patients aged ≤ 50 years without traditional cardiovascular risk factors and healthy controls matched for age and gender. Baseline characteristics, laboratory data, and SpA-related parameters were recorded. All participants underwent ultrasound examination with measurement of EAT thickness, FMD, and cIMT by both an experienced cardiologist and radiologist blinded to clinical data. The relationships between the ultrasound measurements were analyzed using Spearman’s correlation coefficient and Person correlation. Results The study included 94 subjects (47 SpA and 47 healthy controls). The sex-ratio was 2.35; the median age of patients was 36 years (IQR: 28–46), and the median disease duration was 11 years (IQR: 5–16). Compared to the control group, SpA patients had significantly higher values of EAT thickness (p = 0.001) and cIMT (p < 0.0001). FMD values were significantly lower in SpA patients compared to controls (p = 0.008). The univariate analysis detected a significant negative association between EAT thickness and FMD (p = 0.026; r = − 0.325), and between left cIMT and FMD (p = 0.027; r = − 0.322). No association was found between EAT thickness and cIMT. Conclusion EAT thickness, FMD, and cIMT were significantly impaired in SpA patients compared with healthy controls supporting evidence of accelerated atherosclerosis in SpA. EAT thickness was correlated to endothelial dysfunction suggesting the role of EAT in predicting the early reversible stages of atherosclerosis. Key Points • Spondyloarthritis is associated with impaired subclinical atherosclerosis markers accurately increased epicardial fat and carotid intima-media thickness and endothelial dysfunction. • Increased epicardial fat thickness is correlated with impaired endothelial function in spondyloarthritis patients.
- 1 July 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (10) , 3017-3025
Increased epicardial adipose tissue thickness correlates with endothelial dysfunction in spondyloarthritis
Introduction We aimed to investigate the relationship between epicardial adipose tissue (EAT) thickness, flow-mediated dilation (FMD), and carotid intima-media thickness (cIMT) in spondyloarthritis (SpA) patients compared to healthy controls. Methods We performed a cross-sectional study including SpA patients aged ≤ 50 years without traditional cardiovascular risk factors and healthy controls matched for age and gender. Baseline characteristics, laboratory data, and SpA-related parameters were recorded. All participants underwent ultrasound examination with measurement of EAT thickness, FMD, and cIMT by both an experienced cardiologist and radiologist blinded to clinical data. The relationships between the ultrasound measurements were analyzed using Spearman’s correlation coefficient and Person correlation. Results The study included 94 subjects (47 SpA and 47 healthy controls). The sex-ratio was 2.35; the median age of patients was 36 years (IQR: 28–46), and the median disease duration was 11 years (IQR: 5–16). Compared to the control group, SpA patients had significantly higher values of EAT thickness (p = 0.001) and cIMT (p < 0.0001). FMD values were significantly lower in SpA patients compared to controls (p = 0.008). The univariate analysis detected a significant negative association between EAT thickness and FMD (p = 0.026; r = − 0.325), and between left cIMT and FMD (p = 0.027; r = − 0.322). No association was found between EAT thickness and cIMT. Conclusion EAT thickness, FMD, and cIMT were significantly impaired in SpA patients compared with healthy controls supporting evidence of accelerated atherosclerosis in SpA. EAT thickness was correlated to endothelial dysfunction suggesting the role of EAT in predicting the early reversible stages of atherosclerosis. Key Points • Spondyloarthritis is associated with impaired subclinical atherosclerosis markers accurately increased epicardial fat and carotid intima-media thickness and endothelial dysfunction. • Increased epicardial fat thickness is correlated with impaired endothelial function in spondyloarthritis patients.